Evidence map›Paper›PMID 35013835›Full record

ArticleThe AAPS journal2022

Performance Evaluation of Montelukast Pediatric Formulations: Part I-Age-Related In Vitro Conditions.

Mariana Guimarães, Pascal Somville, Maria Vertzoni, Nikoletta Fotaki

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The AAPS journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Mariana GuimarãesDepartment of Pharmacy and Pharmacology, University of Bath, Bath, UK.
Pascal SomvilleUCB Pharma S.A., Product Development, B-1420, Braine l'Alleud, Belgium.
Maria VertzoniDepartment of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
Nikoletta FotakiCentre for Therapeutic Innovation and Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, BA2 7AY, UK. n.fotaki@bath.ac.uk.ORCID http://orcid.org/0000-0003-1826-7363
University of Bath · GBNational and Kapodistrian University of Athens · GRUCB Pharma (Belgium) · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to explore the potential of biopharmaceutics in vitro tools to predict drug product performance in the pediatric population. Biorelevant dissolution set-ups were used to predict how age and medicine administration practices affect the in vitro dissolution of oral formulations of a poorly water-soluble compound, montelukast. Biorelevant age-appropriate dissolution studies of Singulair

Indexed as

AcetatesAdministration, OralAdultAge FactorsAnti-Asthmatic AgentsBiopharmaceuticsChemistry, PharmaceuticalChildCyclopropanesDrug LiberationFood-Drug InteractionsHumansHydrodynamicsInfantLeast-Squares AnalysisPediatricsAcetatesAnti-Asthmatic AgentsCyclopropanesmontelukastQuinolinesSulfidesadultsage-related biorelevant dissolutionbiopharmaceuticsmontelukastpediatrics

Identifiers

PMID35013835
PMCPMC8817206
OpenAlexW4206359285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.